

Wenjie Zheng

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3867225/publications.pdf>

Version: 2024-02-01

29
papers

592
citations

687363

13
h-index

642732

23
g-index

30
all docs

30
docs citations

30
times ranked

677
citing authors

#	ARTICLE	IF	CITATIONS
1	Exosomal microRNA miR-155-5p from PDLSCs regulated Th17/Treg balance by targeting sirtuin1 in chronic periodontitis. <i>Journal of Cellular Physiology</i> , 2019, 234, 20662-20674.	4.1	108
2	Identifying cancer-associated fibroblasts as emerging targets for hepatocellular carcinoma. <i>Cell and Bioscience</i> , 2020, 10, 127.	4.8	51
3	Circulating Exosomes Derived-miR-146a from Systemic Lupus Erythematosus Patients Regulates Senescence of Mesenchymal Stem Cells. <i>BioMed Research International</i> , 2019, 2019, 1-10.	1.9	44
4	Identification and Validation of the N6-Methyladenosine RNA Methylation Regulator YTHDF1 as a Novel Prognostic Marker and Potential Target for Hepatocellular Carcinoma. <i>Frontiers in Molecular Biosciences</i> , 2020, 7, 604766.	3.5	41
5	Secretory clusterin promotes hepatocellular carcinoma progression by facilitating cancer stem cell properties via AKT/GSK-3 β /I χ 2-catenin axis. <i>Journal of Translational Medicine</i> , 2020, 18, 81.	4.4	33
6	DNA primase subunit 1 deteriorated progression of hepatocellular carcinoma by activating AKT/mTOR signaling and UBE2C-mediated P53 ubiquitination. <i>Cell and Bioscience</i> , 2021, 11, 42.	4.8	30
7	B7-H3 participates in human salivary gland epithelial cells apoptosis through NF- κ B pathway in primary Sjögren's syndrome. <i>Journal of Translational Medicine</i> , 2019, 17, 268.	4.4	27
8	The Emerging Roles of Exosomes in the Chemoresistance of Hepatocellular Carcinoma. <i>Current Medicinal Chemistry</i> , 2020, 28, 93-109.	2.4	23
9	Oncogenic Wnt3a: A Candidate Specific Marker and Novel Molecular Target for Hepatocellular Carcinoma. <i>Journal of Cancer</i> , 2019, 10, 5862-5873.	2.5	20
10	USP7 mediates pathological hepatic de novo lipogenesis through promoting stabilization and transcription of ZNF638. <i>Cell Death and Disease</i> , 2020, 11, 843.	6.3	19
11	Diagnostic and prognostic significance of secretory clusterin expression in patients with hepatocellular carcinoma. <i>Tumor Biology</i> , 2016, 37, 999-1008.	1.8	17
12	Flap endonuclease 1 Facilitated Hepatocellular Carcinoma Progression by Enhancing USP7/MDM2-mediated P53 Inactivation. <i>International Journal of Biological Sciences</i> , 2022, 18, 1022-1038.	6.4	17
13	Silencing clusterin gene transcription on effects of multidrug resistance reversing of human hepatoma HepG2/ADM cells. <i>Tumor Biology</i> , 2015, 36, 3995-4003.	1.8	16
14	Oncogenic secretory clusterin in hepatocellular carcinoma: Expression at early staging and emerging molecular target. <i>Oncotarget</i> , 2017, 8, 52321-52332.	1.8	16
15	Advances in the study of oncofetal antigen glypican-3 expression in HBV-related hepatocellular carcinoma. <i>BioScience Trends</i> , 2016, 10, 337-343.	3.4	14
16	Role of secretory clusterin in hepatocarcinogenesis. <i>Translational Gastroenterology and Hepatology</i> , 2018, 3, 48-48.	3.0	14
17	Cyclin-Dependent Kinase Regulatory Subunit 2 Indicated Poor Prognosis and Facilitated Aggressive Phenotype of Hepatocellular Carcinoma. <i>Disease Markers</i> , 2019, 2019, 1-13.	1.3	14
18	Hepatic Stellate Cell: A Potential Target for Hepatocellular Carcinoma. <i>Current Molecular Pharmacology</i> , 2020, 13, 261-272.	1.5	14

#	ARTICLE	IF	CITATIONS
19	Abnormality of Wnt3a expression as novel specific biomarker for diagnosis and differentiation of hepatocellular carcinoma. <i>Tumor Biology</i> , 2016, 37, 5561-5568.	1.8	13
20	High mobility group box 3 as an emerging biomarker in diagnosis and prognosis of hepatocellular carcinoma. <i>Cancer Management and Research</i> , 2018, Volume 10, 5979-5989.	1.9	13
21	Identification and Validation of Ubiquitin-Specific Proteases as a Novel Prognostic Signature for Hepatocellular Carcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 629327.	2.8	11
22	Insulin-like Growth Factor I Receptor: A Novel Target for Hepatocellular Carcinoma Gene Therapy. <i>Mini-Reviews in Medicinal Chemistry</i> , 2019, 19, 272-280.	2.4	7
23	Effects of Extracellular Vesicles Derived from Mesenchymal Stem/Stromal Cells on Liver Diseases. <i>Current Stem Cell Research and Therapy</i> , 2019, 14, 442-452.	1.3	7
24	Biological testing of chitosan-collagen-based porous scaffolds loaded with PLGA/Triamcinolone microspheres for ameliorating endoscopic dissection-related stenosis in oesophagus. <i>Cell Proliferation</i> , 2021, 54, e13004.	5.3	6
25	Rac Family Small GTPase 3 Correlates with Progression and Poor Prognosis in Bladder Cancer. <i>DNA and Cell Biology</i> , 2021, 40, 469-481.	1.9	5
26	Secretory Clusterin as a Novel Molecular-targeted Therapy for Inhibiting Hepatocellular Carcinoma Growth. <i>Current Medicinal Chemistry</i> , 2020, 27, 3290-3301.	2.4	5
27	Loss of BMP-10 is correlated with poor survival in ovarian cancer. <i>Pathology Research and Practice</i> , 2019, 215, 121-126.	2.3	3
28	Secretory Clusterin: A Promising Target for Chemoresistance of Hepatocellular Carcinoma. <i>Mini-Reviews in Medicinal Chemistry</i> , 2020, 20, 1153-1165.	2.4	3
29	Organoid: Current Implications and Pharmaceutical Applications in Liver Diseases. <i>Current Molecular Pharmacology</i> , 2020, 13, 498-508.	1.5	1